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on day +31 due with subsequent normalization of his CBC.
Conclusions: Mobilization with G-CSF and Plerixafor was
well tolerated in AL patients with multiple organs involved.
Limited leukaphereses were needed to achieve or exceed the
target CD34+ cell dose. In the era of more effective initial
therapies, an era in which many AL patients are living longer
with moderate to severe organ damage and receiving mul-
tiple lines of therapy including SCT, this approach allows not
only the collection of sufﬁcient CD34+ cells for optimal im-
mediate stem cell dosing, but also the cryopreservation of
aliquots for future transplants should they become necessary
and for novel cell-based therapies should they become
available.145
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In spite of intensive multimodal therapy including HSCT, it is
difﬁcult to assess remission in NB. We have previously
demonstrated thatWT1is a surrogate marker of proliferation
in leukemia. To assess the status of NB cell proliferation post
HSCT, WT1 gene expression was evaluated. 42 random bone
marrow (BM) samples (from 34 patients) were obtained, at
diagnosis (n¼24) and post HSCT (n¼18; 13 in remission and
5 in clinical relapse). Quantitative RT-PCR was used for the
evaluation of the level of gene expression as positive (> 1 x
100 ng/ml), weakly positive (9.9 x 10-1 to 6.5 x 10-1 ng/ml) and
negative (< 6.5 x 10-1 ng/ml). Results were extrapolated from
a ten fold serial dilution standard curve using a NB cell line
(NGP). The levels of WT1 gene expression in NGP were
arbitrarily deﬁned as 1.0. The integrity of RNAwas conﬁrmed
by ampliﬁcation of the housekeeping gene GAPDH. At diag-
nosis 83% (18/24 positive, 2/24 weakly positive) (95.9 + 74.2
(0.890- 1500) ng/ml) patients expressed theWT1 gene, where
17% (4/24) (0.199 + 0.0946 (0.007- 0.440) ng/ml) were nega-
tive. Post HSCT in remission 92% (12/13) were negative
(0.0822 + 0.0192 (0.0026-0.200) ng/ml) in comparison to the
time of clinical relapse where 60% (3/5) (1.57 + 0.418 (1.10 e
2.40) ng/ml) were positive for WT1 gene expression. A com-
parison t-test was performed between the initial gene
expression at diagnosis to remission and only positive WT1
gene expression at diagnosis to clinical relapse. Signiﬁcant
difference (p<.0002) was found when comparing WT1
transcription at diagnosis to remission, whereas insigniﬁ-
cance (p<.5) was found when comparing positive WT1
expression at diagnosis to clinical relapse. This signiﬁes that
the WT1 gene is indicative of cellular proliferation further
illustrating the status of BM involvement in NB patients post
HSCT.146
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AuHCT is commonly an inpatient procedure. Due to im-
provements in supportive care, many centers now perform
AuHCT on an outpatient basis. We compared the outcome of
95 outpatients (OP) and 135 inpatients (IP) that underwent a
ﬁrst AuHCT from July 2009 to December 2012 formyeloma or
lymphoma usingmelphalan or BEAM conditioning at a single
center. Selection for OP AutoHCT was based on expected
compliance, proximity to the cancer center for daily visits,
24-hour caregiver support, and favorable performance status
and co-morbidity proﬁle. Both groups received the same
chemotherapy or supportive care, except that the OP group
received more aggressive prophylactic antibiotic support
during neutropenia and received pegﬁlgrastim on day +1.
The IP group received daily ﬁlgrastim starting on day +5.
The OP and IP cohorts were similar in terms of primary
disease (myeloma vs. lymphoma), median age, gender, and
chemo-sensitivity pre-transplant. Karnofsky Performance
Status (KPS) was less favorable in the IP cohort with KPS80
in 36% vs. 6% in the OP cohort (p<.001). There was a trend
toward less favorable Hematopoietic Cell Transplant Co
morbidity Index (HCT-CI) in the IP cohort as well with 53% of
the patients having HCT-CI >/¼3 vs. 40% in the OP cohort
(p¼.060). With regard to transplant characteristics, OP and IP
received a similar CD34 cell dose (4.4 vs. 4.6 x 106/kg,
respectively, p¼.581). Hematopoietic recovery occurred
earlier in the OP cohort, with median time to neutrophil
recovery of 10 vs. 11 days (p<.001) and median time to
platelet recovery of 19 vs. 20 days (p¼.053). For OP AuHCT,
overall 51%were never admitted; for patients transplanted in
2011-2012 this ﬁgure was 61%. For the OP that were
admitted, median length of stay was 9 days. In comparison,
the IP AuHCT patients had a median length of stay of 19 days.
Grade 3-4 non-hematologic toxicities occurred in 29% of both
the OP and IP cohorts. There were no signiﬁcant differences
in speciﬁc adverse events between the two cohorts,
including febrile neutropenia, bacteremia, Clostridium difﬁ-
cile infections, central venous line complications, and
engraftment syndrome. Non-relapse mortality at one year
was 0% in the OP cohort and 1.5% in the IP cohort (p¼.327).
Two year PFS was 62% for OP vs. 54% for IP (p¼.155). One and
two year OS was 97% and 83% for OP vs. 91% and 80% for IP,
respectively (p¼.271).
We conclude that, with careful patient selection and minor
modiﬁcation to the management of neutropenia, OP AuHCT
can result in excellent outcomes for myeloma and lymphoma
patients. OPAuHCT also offers beneﬁt for patients in terms of
enhanced comfort, fewer days in the hospital, and decreased
exposure to sick contacts. Lastly, OP AuHCT is beneﬁcial to
transplant centers due to decreased hospital resource utili-
zation.147
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Introduction: Busulfan (BU) and etoposide (VP) have been
employed as preparative therapy for autologous stem cell
transplantation (autoSCT) in adults with acute myeloid leu-
kemia (AML) for over 20 years. Toxicity and safety signiﬁ-
cantly improved with the transition from oral to intravenous
(IV) BU and the use of pharmacokinetic (PK)-based dosing. In
an attempt to enhance outcomes following autoSCT, we
designed a Phase I study with the following objectives: 1) to
determine the maximum tolerated dose (MTD) of targeted,
dose-escalated IV BU in combination with VP- 60mg/kg and
2) to achieve BU levels within +/- 10% of goal in >80% of
patients (pts) after dose-adjustment (DA).
Methods: Patients with AML in CR1 meeting all eligibility
criteria including, ECOG 0-1, age 18-69, good organ function,
and adequate stem cells stored (>3 x 10e6 CD34 following
consolidation chemotherapy (HDAC+VP)) were prospectively
enrolled. Three cohorts (targeted AUC 1250, 1400 and 1550
mMol*minwere plannedwith Cohort 1 (C1) receiving IV BU at
0.9mg/kg, Cohort 2 (C2) at 1 mg/kg and Cohort 3 (C3) at BU
1.1mg/kg. PK studies were performed after doses 1 (day -10),
4, and 12, with DA occurring with doses 2 and 11 of 16 total
doses. VP was given IV on day -3 with autoSCT on day 0.
Palifermin and standard antimicrobial prophylaxis were used.
Results: To date, 12 pts have undergone autoSCT with tar-
geted, dose-escalated IV BU. Median age 50 (range 24-61).
Cytogenetics were diploid in 5 (1 FLT3+, 2 FLT3 WT, 2 FLT3
unknown). The remaining 7 pts had t(9;11) (2), +21 (2),
t(8;21), 9q-, and 1 failed. TRM was 0% and engraftment
robust; mean ANC >500/uL and platelets >20,000/uL was 11
(range 10-13) and 30 days (range 13-124), respectively.
All pts received a DA after dose #1 and 7 (58.3%) prior to
dose #11. Themean ﬁnal AUCwas 1243 (range 1151-1361) for
C1 and 1464 (range 1401-1558) for C2. All pts in C1 were
within 10% of the target AUC in C1 (range -2.8 to +8.2%)
versus 83% in C2 (range +0.1 to +10.1%). PK studies revealed
BU accumulation at dose 12, with the ﬁnal AUC exceeding
goal by a mean of 14.9% (range 1-35%). Grade 3-4 mucositis
occurred in 50% in C1 and in 66% in C2. Grade 3 hepatic
dysfunction was observed in 33% in C1 and in none in C2.
As of October 2013, 50% of pts are alive and relapse-free.
Median relapse-free survival (RFS) for the entire study group
is 12.6 months (range 2.2-28.9). In C1, RFS is 33% (median13.1
months; range 3.0-28.9) vs. 66% in C2 (median 12.2 months;
range 2.2-20.6). Non-relapse mortality (NRM) was 0% at 100
days post-autoSCT.
Conclusions: Targeted, dose-escalated IV BU in combination
with VP as preparative therapy for autoSCT in AML is safe,
with mucositis being the most signiﬁcant toxicity, limiting
escalation to C3. An AUC target of 1400 was deemed the
maximum acceptable dose. Serum BU levels accumulate,
with higher-than-expected ﬁnal AUC despite interval DA
based on PK studies. Increased BU AUC target is associated
with improved RFS at one year.148
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Background: Although autologous stem cell transplant
(ASCT) can be curative for patients (pts) with relapsed/re-
fractory Hodgkin lymphoma (HL), those with high-risk dis-
ease have long-term progression-free survival (PFS) of
approximately 25% and could beneﬁt from novel thera-
peutic approaches (Majhail 2006). Brentuximab vedotin
(ADCETRIS) comprises an anti-CD30 antibody conjugated
by a protease-cleavable linker to a microtubule-disrupting
agent, monomethyl auristatin E (MMAE). In a pivotal phase 2
study in pts with relapsed or refractory HL following ASCT,
the objective response rate was 75%, with complete re-
missions (CR) in 33% of pts. A phase 3 study was initiated to
evaluate the potential of brentuximab vedotin to prevent
relapse post-ASCT in pts at high risk of lymphoma progres-
sion (ClinicalTrials.gov #NCT01100502).
Methods: The AETHERA trial is a phase 3, randomized,
double-blind, placebo-controlled, multicenter study. After
ASCT, pts received brentuximab vedotin 1.8 mg/kg q3wk and
best supportive care (BSC) or placebo and BSC for up to 16
cycles (approximately 12 months). The primary endpoint is
PFS per independent review; additional endpoints include
overall survival and safety/tolerability. A planned interim
safety and futility analysis was performed in Q4 2012; at that
time 1214/1251 (97%) of the expected CT scans had been
received for central independent review.
Patient Characteristics/Results: Protocol enrollment
occurred from April 2010 through September 2012. A total of
329 pts were enrolled and randomized; of these, 327
received study treatment. Of the 327 pts, 133 (40%) were
enrolled from the United States, 48 (15%) from Western
Europe, and 146 (45%) from Central/Eastern Europe and
Russia. The median age was 32 years (range 18e76) and
52.6% were male. Pts were enrolled in 1 of 3 high-risk cate-
gories: refractory to frontline therapy: 195 pts (59.6%),
relapse <12 months after frontline therapy: 107 pts (32.7%),
and relapse 12 months after frontline therapy with extra-
nodal disease: 25 pts (7.6%). Response to salvage pre-ASCT
was CR: 122 pts (37.3%), PR: 112 pts (34.3%), and SD: 93 pts
(28.4%). Overall, 33% of pts were known to be PET-negative
prior to ASCT. ASCT conditioning regimens were carmustine,
etoposide, cytarabine, and melphalan (BEAM; 61%), cyclo-
phosphamide, carmustine, and etoposide (CBV; 11%), or
other (28%) and included radiation in 6% of pts. All pts were
off treatment as of August 2013. The median number of
